The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced neuroendocrine carcinoma.
 
Jianming Xu
No Relationships to Disclose
 
Hanguang Hu
No Relationships to Disclose
 
Ming Lu
No Relationships to Disclose
 
Chenyu Mao
No Relationships to Disclose
 
Wei Wang
No Relationships to Disclose
 
Jianwei Yang
No Relationships to Disclose
 
Fei Yin
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Xiaoyan Lin
No Relationships to Disclose
 
Yanjun Mi
No Relationships to Disclose
 
Xinjun Liang
No Relationships to Disclose
 
Zhihu Li
No Relationships to Disclose
 
Jingdong Zhang
No Relationships to Disclose
 
Kangsheng Gu
No Relationships to Disclose
 
Ying Liu
No Relationships to Disclose
 
Jason Wu
Employment - Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Leadership - Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Stock and Other Ownership Interests - Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Honoraria - Suzhou Zelgen Biopharmaceuticals Co., Ltd.